AI Article Synopsis
- - Graves' disease is an autoimmune condition that leads to hyperthyroidism, exhibiting symptoms such as tremors, weight loss, and heat intolerance, while also potentially causing liver issues.
- - A rare case highlighted involves Graves' thyrotoxicosis where the patient experienced severe cholestasis and high calcium levels, with thorough tests for liver problems coming back negative.
- - The patient improved after treatment with methimazole, leading to better clinical and biochemical outcomes.
Article Abstract
Graves' disease (GD) is an autoimmune thyroid disease, which is considered the most common cause of primary hyperthyroidism. GD usually manifests with symptoms such as tremors, palpitations, heat intolerance, weight loss, and specific signs on physical examination (proptosis and pretibial myxedema). However, systemic involvement is also recognized, for example, hepatic involvement in patients with GD may range from asymptomatic laboratory findings of liver function derangement (either transaminases elevations or intrahepatic cholestasis) up to hepatic failure. We describe a rare case of Graves' thyrotoxicosis presenting with severe cholestasis and non-parathyroid hormone-related hypercalcemia. An extensive evaluation for hepatobiliary causes of cholestasis, including hepatic biopsy, was entirely negative. The patient was successfully treated with methimazole with subsequent clinical and biochemical improvement.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031658 | PMC |
| http://dx.doi.org/10.7759/cureus.35206 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Progressive Cachexia: Tuberculosis, Cancer, or Thyrotoxicosis? Disease-Directed Therapy and Atypical Courses of Autoimmune and Malignant Thyroid Diseases in a High Specialization Era: Case-Control Study with a Critical Literature Review.
Biomedicines
November 2024
Department of Pharmacognosy and Herbal Medicines, Wroclaw Medical University, 50-367 Wrocław, Poland.
Critical and progressive cachexia may be observed in numerous medical disciplines, but in patients with various diseases, several pathways overlap (endocrine, inflammatory and kidney diseases, heart failure, cancer). Unlike numerous cohort studies that examine thyroid cancer and risk factors, a different method was used to avoid bias and analyze the sequence of events, i.e.
View Article and Find Full Text PDFThe Impact of Maternal Graves' Disease on Neonatal Thyroid Function: A Systematic Review.
Cureus
December 2024
Department of Midwifery, School of Health and Care Sciences, University of West Attica, Athens, GRC.
Maternal Graves' disease (GD) poses a significant risk to neonatal thyroid function due to the transplacental transfer of thyrotropin receptor antibodies (TRAbs). This systematic review aims to assess the impact of maternal GD on neonatal thyroid outcomes and identify key maternal factors influencing these outcomes. A comprehensive literature search was conducted across PubMed, Scopus, and Cochrane, resulting in the inclusion of 18 studies published from 2014 to 2024.
View Article and Find Full Text PDFPediatric Graves' disease in Argentina: analyzing treatment strategies and outcomes.
J Pediatr Endocrinol Metab
December 2024
CONICET-FEI-División de Endocrinología, Centro de Investigaciones Endocrinológicas"Dr. César Bergadá" (CEDIE), Hospital de Niños Ricardo Gutiérrez, BuenosAires, Argentina.
Objectives: Graves' disease is the leading cause of hyperthyroidism in children. Only a small percentage of pediatric patients achieve remission with anti-thyroid drug treatment (ATD), and both definitive therapies (thyroidectomy, or radioiodine thyroid ablation) cause lifelong hypothyroidism. Our objective was to evaluate the outcome of patients with pediatric Graves' disease (PGD), treated at a single tertiary center, focusing on response to medical treatment, remission rate, adverse reactions (AR), definitive treatment (DT), and potential predictive factors for remission.
View Article and Find Full Text PDFManagement of perioperative thyrotoxicosis - what to do when standard therapy is contraindicated or fails?
Front Endocrinol (Lausanne)
December 2024
Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.
Background: Current guidelines recommend that hyperthyroid patients should be rendered euthyroid prior to surgical procedures. These guidelines rely heavily on the use of ATDs as the primary medication, and do not give recommendations for patients who have contraindications to ATDs, or for whom standalone ATD treatment is inadequate.
Objectives: To evaluate the efficacy and safety of adjunctive pharmacological therapy and/or therapeutic plasma exchange (TPE) in the perioperative management of patients with thyrotoxicosis who were intolerant to ATD or for whom standalone ATD therapy was inadequate to achieve euthyroidism prior to surgery.
Introduction: Thyrotoxic hypokalemic periodic paralysis (THPP) is a rare but severe complication of hyperthyroidism characterized by acute muscle weakness. This study reports the first case of THPP in an adolescent with type 1 diabetes mellitus (T1DM) and Graves' disease, triggered by high-dose insulin, high carbohydrate intake, and strenuous exercise. It highlights the clinical presentation, management, and implications of THPP in this context.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!